Company
Every investor coverage indicates participated in a round Cynata Therapeutics raised.
Companies Cynata Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Cynata Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Acrux has hired Dr Jolanta Airey as chief medical officer, adding clinical leadership as the company prepares late-stage trials in the United States for its women's testosterone therapy.
Techboard's September 2022 roundup reports Australian raises led by Morse Micro's $140m Series B, several acquisitions including ResApp Health to Pfizer, fund closes by Telstra Ventures, OIF and Main Sequence, and open raises.